Arbutus Biopharma Corp ABUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
-
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
-
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
-
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech — Update
-
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech
-
Arbutus Biopharma Gets FDA Fast-Track Designation for Imdusiran in Chronic Hepatitis B
Trading Information
- Previous Close Price
- $4.29
- Day Range
- $4.18–4.29
- 52-Week Range
- $3.50–5.45
- Bid/Ask
- $4.07 / $4.22
- Shares Outstanding
- 153.28M
- Market Cap
- $836.01M
- Volume/Avg
- 5M / 5M
Key Statistics
- Price/Earnings (Normalized)
- 5.26
- Price/Sales
- 4.40
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 19
- Website
- http://www.arbutusbio.com
Valuation
|
Metric
|
ABUS
|
|---|---|
Price/Earnings (Normalized) | 5.26 |
Price/Book Value | 3.14 |
Price/Sales | 4.40 |
Price/Cash Flow | 5.21 |
Price/Earnings
ABUS
Financial Strength
|
Metric
|
ABUS
|
|---|---|
Quick Ratio | 80.97 |
Current Ratio | 81.42 |
Interest Coverage | 1,969.00 |
Quick Ratio
ABUS
Profitability
|
Metric
|
ABUS
|
|---|---|
Return on Assets (Normalized) | 92.01% |
Return on Equity (Normalized) | 103.08% |
Return on Invested Capital (Normalized) | 100.65% |
Return on Assets
ABUS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<nhpSk | LOCK|$js^d | $127B | |||
| Moderna Inc
MRNA
| LOCK|??%Vw<& | LOCK|fkg | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|CZsw!Q | LOCK|fm<& | $81B | |||
| argenx SE ADR
ARGX
| LOCK|z!##<? | LOCK|$J | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#hh><K& | LOCK|## | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|DFL%^%? | LOCK|CH!>d | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Hn<?rv> | LOCK|S?fPF | $27B | |||
| Incyte Corp
INCY
| LOCK|#^!%k!v | LOCK|&% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|YZMys&< | LOCK|Yrx | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^$JM^%g | LOCK|?%q | $14B |
United States